Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GIB-7 + GI-102
- Development stage
- Unknown
- Lead developer
- GI Innovation
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
**GIB-7 + GI-102** is a Phase 2 combination therapy being developed by GILongevity for **health span** extension in the **GIANTS-1** trial. The regimen combines **GIB-7**, a microbiome-based synbiotic/health functional food developed from GI Biome technology, with **GI-102**, a clinical-stage **CD80/IL2v3** immunocytokine from GI Innovation. Mechanistically, the combination is intended to pair microbiome modulation and host physiological support from GIB-7 with low-dose immune stimulation from GI-102, which has been described as selectively expanding and activating **natural killer cells** to promote clearance of senescent cells and cellular debris. The program is positioned as a novel anti-aging and healthy-aging approach aimed at extending healthspan rather than treating a conventional single-organ disease indication.
- Other names
- GIANTS-1 trial combination therapyGIANTS1 trial combination therapyGIANTS 1 trial combination therapy
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on GIB-7 + GI-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GIB-7 + GI-102.